Protective Effects of Lithium on Sumatriptan-Induced Memory Impairment in Mice
Lithium is a drug used for the treatment of bipolar disorder. It has several mechanisms of action, and recently it is shown that lithium can antagonize the 5-HT1B/1D serotonin receptors. Sumatriptan is a 5-HT1B/1D receptor agonist used for the treatment of cluster headaches and migraine which might cause memory impairment as a potential side effect. In this study, effects of lithium on sumatriptan-induced memory impairment have been determined in a two-trial recognition Y-maze and passive avoidance tests. Male mice weighing 25-30 g were divided into several groups randomly. In Y-maze test, effects of lithium (1,5,10,20,40,80 mg/kg) and sumatriptan (1,5,10 mg/kg) were assessed on memory acquisition, then lithium (0.1,1,10 mg/kg) and sumatriptan (1,10 mg/kg) were studied in passive avoidance test. Effects of lithium (1mg/kg) on sumatriptan (10 mg/kg)-induced memory impairment were studied in both of tests. The present study demonstrated that sumatriptan impaired memory in Y-maze and passive avoidance tests (P<0.05, P<0.01, respectively). Lithium did not show any significant effect on memory function compared to saline-treated control group in both tests (P>0.05), but significantly reversed sumatriptan-induced memory impairment in Y-maze and passive avoidance tests (P<0.001, P<0.05, respectively). It is concluded that lithium reverses the sumatriptan-induced memory impairment probably through 5-HT1B/1D receptors antagonism.
Razzaque Z, Heald M, Pickard J, Maskell L, Beer M, Hill R, et al. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT~ 1~ B-and 5-HT~ 1~ P-receptor activation. British journal of clinical pharmacology. 1999;47:75-82.
Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J. Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study. European neuropsychopharmacology. 2005;15(3):279-82.
Feuerstein TJ, Hüring H, van Velthoven V, Lücking CH, Landwehrmeyer GB. 5-HT< sub> 1D-like receptors inhibit the release of endogenously formed [< sup> 3 H] GABA in human, but not in rabbit, neocortex. Neuroscience letters. 1996;209(3):210-4.
McCreary AC, Bankson MG, Cunningham KA. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B/1D receptors. Journal of Pharmacology and Experimental Therapeutics. 1999;290(3):965-73.
Lin D, Parsons LH. Anxiogenic-like effect of serotonin< sub> 1B receptor stimulation in the rat elevated plus-maze. Pharmacology Biochemistry and Behavior. 2002;71(4):581-7.
Popova N, Amstislavskaya T. Involvement of the 5-HT< sub> 1A and 5-HT< sub> 1B serotonergic receptor subtypes in sexual arousal in male mice. Psychoneuroendocrinology. 2002;27(5):609-18.
Ekbom K, Monstad I, Prusinski A, Cole J, Pilgrim A, Noronha D, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurologica Scandinavica. 1993;88(1):63-9.
Tsaltas E, Kontis D, Boulougouris V, Papakosta V-M, Giannou H, Poulopoulou C, et al. Enhancing effects of chronic lithium on memory in the rat. Behavioural brain research. 2007;177(1):51-60.
Medina M, Avila J. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Current pharmaceutical design. 2010;16(25):2790-8.
Maguschak KA, Ressler KJ. The dynamic role of beta-catenin in synaptic plasticity. Neuropharmacology. 2012;62(1):78-88.
Ghasemi M, Dehpour AR. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends in pharmacological sciences. 2011 Jul;32(7):420-34. PubMed PMID: 21492946. Epub 2011/04/16. eng.
Allami N, Javadi-Paydar M, Rayatnia F, Sehhat K, Rahimian R, Norouzi A, et al. Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. European journal of pharmacology. 2011;650(1):240-8.
Javadi-Paydar M, Rayatnia F, Fakhraei N, Zakeri M, Mirazi N, Norouzi A, et al. Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: involvement of nitric oxide. Brain research. 2011;1386:89-99.
Creson TK, Woodruff ML, Ferslew KE, Rasch EM, Monaco PJ. Dose–response effects of chronic lithium regimens on spatial memory in the black molly fish. Pharmacology Biochemistry and Behavior. 2003;75(1):35-47.
Latalova K, Prasko J, Diveky T, Velartova H. Cognitive impairment in bipolar disorder. Biomedical Papers. 2011;155(1):19-26.
Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. The Journal of clinical psychiatry. 2008;69(5):712-9.
Meneses A. Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Reviews in the Neurosciences. 1998;9(4):275-90.
Slassi A. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Current topics in medicinal chemistry. 2002;2(6):559-74.
Meneses A, Hong E. 5-HT< sub> 1A Receptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats. Neurobiology of learning and memory. 1999;71(2):207-18.
Malleret G, Hen R, Guillou J-L, Segu L, Buhot M-C. 5-HT1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze. The Journal of neuroscience. 1999;19(14):6157-68.
Schechter L, Dawson L, Harder J. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer's disease. Current pharmaceutical design. 2002;8(2):139-45.
Harder J, Ridley R. The 5-HT< sub> 1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology. 2000;39(4):547-52.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.